LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "ravulizumab" as a keyword



Photo from wikipedia

Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

Sign Up to like & get
recommendations! Published in 2023 at "Annals of Neurology"

DOI: 10.1002/ana.26626

Abstract: CHAMPION‐NMOSD (NCT04201262) is a phase 3, open‐label, externally controlled interventional study evaluating the efficacy and safety of the terminal complement inhibitor ravulizumab in adult patients with anti–aquaporin‐4 antibody–positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab… read more here.

Keywords: neuromyelitis optica; spectrum disorder; ravulizumab; optica spectrum ... See more keywords
Photo from wikipedia

Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients

Sign Up to like & get
recommendations! Published in 2020 at "International Journal of Hematology"

DOI: 10.1007/s12185-020-02934-6

Abstract: Ravulizumab demonstrated noninferior efficacy and comparable safety to eculizumab in two open-label, phase 3 studies in patients with paroxysmal nocturnal hemoglobinuria (PNH) who complement inhibitor-naive (Study 301) or were previously treated with eculizumab (Study 302).… read more here.

Keywords: ravulizumab; study; japanese patients; eculizumab ... See more keywords
Photo by schluditsch from unsplash

Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome

Sign Up to like & get
recommendations! Published in 2021 at "Drugs"

DOI: 10.1007/s40265-021-01481-6

Abstract: Ravulizumab (Ultomiris®), a humanized monoclonal antibody that inhibits complement protein C5, is indicated for the treatment of atypical haemolytic uraemic syndrome (aHUS) in several countries, including the USA and those of the EU. Ravulizumab has… read more here.

Keywords: treatment; uraemic syndrome; ravulizumab; atypical haemolytic ... See more keywords

Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.

Sign Up to like & get
recommendations! Published in 2021 at "Current medical research and opinion"

DOI: 10.1080/03007995.2021.1971182

Abstract: OBJECTIVE In the absence of a head-to-head study, we assessed the comparative effectiveness of pegcetacoplan, a targeted C3 complement inhibitor, vs. ravulizumab, a C5 complement inhibitor, among patients with paroxysmal nocturnal hemoglobinuria (PNH) previously treated… read more here.

Keywords: treated eculizumab; ravulizumab; pegcetacoplan; comparative effectiveness ... See more keywords
Photo by schluditsch from unsplash

Ravulizumab for the treatment of myasthenia gravis

Sign Up to like & get
recommendations! Published in 2023 at "Expert Opinion on Biological Therapy"

DOI: 10.1080/14712598.2023.2185131

Abstract: ABSTRACT Introduction Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on nonselective immunosuppression with oral steroids and non-steroidal immunosuppressants, mainly with good clinical response.… read more here.

Keywords: myasthenia gravis; ravulizumab treatment; ravulizumab; treatment myasthenia ... See more keywords
Photo by ldxcreative from unsplash

Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

Sign Up to like & get
recommendations! Published in 2023 at "Expert Review of Clinical Pharmacology"

DOI: 10.1080/17512433.2023.2209317

Abstract: ABSTRACT Introduction Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are two rare and severe conditions caused by chronic complement (C’) system dysregulation. Treatment with eculizumab, a recombinant, humanized monoclonal antibody against complement… read more here.

Keywords: atypical hemolytic; nocturnal hemoglobinuria; ravulizumab; uremic syndrome ... See more keywords
Photo by sharonmccutcheon from unsplash

MO020EFFICACY AND SAFETY OF THE LONG-ACTING C5 INHIBITOR RAVULIZUMAB IN PATIENTS WITH POSTPARTUM ATYPICAL HAEMOLYTIC URAEMIC SYNDROME

Sign Up to like & get
recommendations! Published in 2020 at "Nephrology Dialysis Transplantation"

DOI: 10.1093/ndt/gfaa140.mo020

Abstract: Atypical haemolytic uraemic syndrome (aHUS) triggered by pregnancy is a rare and under-recognised disease caused by dysregulation of the alternative complement pathway that occurs in approximately 1 in 25,000 pregnancies. The 311 phase 3 trial… read more here.

Keywords: patients postpartum; inhibitor; ravulizumab; atypical haemolytic ... See more keywords
Photo from wikipedia

Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome

Sign Up to like & get
recommendations! Published in 2022 at "Transplantation Direct"

DOI: 10.1097/txd.0000000000001289

Abstract: D editor, we here report the first case of successful living donor kidney transplantation using complement inhibition by ravulizumab in a 33-y-old woman suffering from hereditary atypical hemolytic uremic syndrome (aHUS). Atypical HUS is the… read more here.

Keywords: kidney; patient; transplantation; kidney transplantation ... See more keywords
Photo by tomspentys from unsplash

Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness

Sign Up to like & get
recommendations! Published in 2022 at "British Journal of Clinical Pharmacology"

DOI: 10.1111/bcp.15602

Abstract: Ravulizumab is an expensive complement C5‐inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria. Recently, a subcutaneous formulation has entered the market, for which the approved dosing regimen results in supratherapeutic ravulizumab concentrations in the majority… read more here.

Keywords: subcutaneous ravulizumab; dose optimalization; patient friendliness; ravulizumab ... See more keywords

First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient

Sign Up to like & get
recommendations! Published in 2022 at "Transplant International"

DOI: 10.3389/ti.2022.10846

Abstract: Dear Editors, Ravulizumab is a long-acting C5-complement monoclonal antibody developed through targeted modifications of eculizumab to significantly extend the half-life of the drug with comparable affinity and specificity to eculizumab (approx. 52 days vs. approx.… read more here.

Keywords: transplant; report; patient; ravulizumab ... See more keywords